Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
GXAI
Gaxos.ai
Sponsored
content by Gaxos.ai
JO
Jolt_Communications
Community Contributor
Gaxos.ai: Early-Stage AI Innovator in Gaming & Health
Key Takeaways Dual AI focus – Gaxos.ai builds AI-powered tools for game developers (via Unity integrations) and AI-driven health services under its RNK Health brand. First signs of commercial traction – After years of development, the company reported ~$24k in H1 2025 revenue, mainly from wellness pilot programs.
View narrative
US$2.21
FV
6.8% undervalued
intrinsic discount
119.00%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
5
users have followed this narrative
New
narrative
Microsoft
PI
PicaCoder
Community Contributor
After the AI Party: A Sobering Look at Microsoft's Future
The world has been captivated by the artificial intelligence boom, and no company has ridden the wave of investor enthusiasm quite like Microsoft. Buoyed by its strategic partnership with OpenAI and the integration of AI across its product ecosystem, the company's valuation has soared to unprecedented heights.
View narrative
US$500.00
FV
2.0% overvalued
intrinsic discount
6.75%
Revenue growth p.a.
Set Fair Value
7
users have liked this narrative
1
users have commented on this narrative
17
users have followed this narrative
8 days ago
author updated this narrative
Amazon.com
ZW
Zwfis
Community Contributor
Amazon's Future Rises as Stock Price Falls: A Long-Term Investment Vision
Amazon is a stock I am very interested in right now especially with the recent price drops that it has been experiencing since its 2Q25 results. A summary of Amazon as stated by Fiscal.ai: "Amazon.com, Inc.
View narrative
US$234.75
FV
2.9% undervalued
intrinsic discount
13.60%
Revenue growth p.a.
Set Fair Value
8
users have liked this narrative
1
users have commented on this narrative
11
users have followed this narrative
New
narrative
Verve Group
TI
TibiT
Community Contributor
Verve Group: A Tale of Three Futures
Verve Group stands at a critical juncture. After a history of explosive growth, the company has been hit by significant operational headwinds, primarily the difficult and costly migration to a unified technology platform and unfavorable currency exchange rates.
View narrative
€4.02
FV
47.4% undervalued
intrinsic discount
8.50%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
3
users have followed this narrative
Updated
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
Lantheus Holdings
AN
AnalystLowTarget
Consensus Narrative from 13 Analysts
PSMA PET Pricing Will Erode Margins Despite Diversification
Key Takeaways Pricing pressures, reimbursement challenges, and reliance on a few key products heighten risk of margin compression and revenue volatility. Product pipeline and partnerships offer diversification potential, but integration hurdles and regulatory headwinds may limit growth and profitability.
View narrative
US$63.00
FV
12.5% undervalued
intrinsic discount
3.84%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
4 days ago
author updated this narrative
Ciena
AN
AnalystLowTarget
Consensus Narrative from 16 Analysts
Slow Data Demand And Concentrated Customers Will Undermine Outlook
Key Takeaways Ciena faces slowing growth and profit pressures due to market saturation, margin erosion from hardware commoditization, and dependence on a few large cloud customers. Geopolitical risks, supply chain uncertainty, and a shift toward lower-margin products threaten near-term revenue visibility and long-term earnings stability.
View narrative
US$66.00
FV
34.5% overvalued
intrinsic discount
9.96%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
2
users have followed this narrative
4 days ago
author updated this narrative
Talen Energy
AN
AnalystLowTarget
Consensus Narrative from 13 Analysts
Decarbonization Pressures Will Erode Legacy Fossil Assets
Key Takeaways Heavy reliance on natural gas and conventional assets heightens exposure to decarbonization, regulatory, and market risks, potentially eroding market share and compressing revenue. Rising competition from renewables and decentralized energy could undermine core operations, reduce contract values, and further pressure earnings and asset values.
View narrative
US$325.57
FV
13.1% overvalued
intrinsic discount
14.19%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
4 days ago
author updated this narrative
Halozyme Therapeutics
AN
AnalystLowTarget
Consensus Narrative from 9 Analysts
Biosimilar Competition And Pricing Pressures Will Erode Biologic Margins
Key Takeaways Heavy dependence on ENHANZE exposes the company to heightened risk from patent expirations, competition, and industry shifts in drug delivery technologies. Intensifying pricing pressure and pharma sector consolidation threaten future profitability, reducing the value of licensing deals and eroding recurring earnings.
View narrative
US$51.00
FV
37.2% overvalued
intrinsic discount
14.52%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
4 days ago
author updated this narrative
Amkor Technology
AN
AnalystLowTarget
Consensus Narrative from 8 Analysts
US And European Onshoring Will Shrink Core Asian Packaging
Key Takeaways Manufacturing onshoring, geopolitical shifts, and rising in-house competition threaten Amkor's core business, revenue stability, and margins. Heavy investments risk overcapacity and obsolescence if demand or technology adoption stalls, pressuring returns and long-term growth.
View narrative
US$19.00
FV
24.9% overvalued
intrinsic discount
3.66%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
4 days ago
author updated this narrative
Cirrus Logic
AN
AnalystLowTarget
Consensus Narrative from 6 Analysts
Smartphone Exposure And Escalating Tensions Will Compress Margins
Key Takeaways Heavy reliance on major smartphone customers and slow diversification leaves the company vulnerable to fluctuating device demand and stalled long-term growth. Rising industry competition, higher input costs, and increasing R&D spending threaten profit margins and future cash flow.
View narrative
US$90.84
FV
24.5% overvalued
intrinsic discount
-0.55%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
4 days ago
author updated this narrative
Coty
AN
AnalystLowTarget
Consensus Narrative from 16 Analysts
Legacy Beauty Brands Will Decline Though Niche Demand Will Persist
Key Takeaways Shifting consumer preferences and digital-native competitors threaten Coty's legacy brands, market share, and pricing power across both mass and prestige segments. Macroeconomic headwinds, cost inflation, and operational risks from portfolio changes place pressure on profitability, margins, and sustainable earnings growth.
View narrative
US$4.00
FV
22.3% overvalued
intrinsic discount
1.43%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
4 days ago
author updated this narrative
Fabrinet
AN
AnalystLowTarget
Consensus Narrative from 8 Analysts
Rising Protectionism And Labor Costs Will Limit Future Margins
Key Takeaways Heightened global protectionism, labor cost pressures, and customer concentration significantly threaten Fabrinet's margins, revenue stability, and long-term profitability. Rapid technological advances and industry commoditization could outpace Fabrinet's investments, shrinking its addressable market and eroding future growth and earnings power.
View narrative
US$184.00
FV
55.0% overvalued
intrinsic discount
16.42%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
4 days ago
author updated this narrative
Axalta Coating Systems
AN
AnalystLowTarget
Consensus Narrative from 18 Analysts
Sluggish North America Demand Will Exert Pressure Yet Unlock Value
Key Takeaways Sluggish repair volume and distributor restocking in key regions, alongside persistent destocking, could continue to weigh on Axalta's revenue and sales volumes recovery. Competitive pressures, rising input costs, and slower commercialization of innovations may constrain Axalta's ability to expand margins and sustain earnings growth.
View narrative
US$30.00
FV
3.6% overvalued
intrinsic discount
1.93%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
4 days ago
author updated this narrative
Value any company in seconds
Popular companies